| News for nuclear medicine and molecular imaging professionals |  |
| |
|
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple
internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher.
The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may
be directed to SmartBrief at snmmi@smartbrief.com.
|
| Top Story
|  |  |
|
- PET/CT better than standard tests for advanced breast cancer
 FDG-PET/CT performed better than standard imaging, including bone scans, chest radiography and CT scans, in accurately detecting lesions in the chest, abdomen and bones in patients with locally advanced breast cancer, according to a study published in the Journal of Nuclear Medicine. FDG-PET/CT also modified disease staging in 52% of patients, allowing for an improvement in treatment. FDG-PET/CT identified distant metastases in 37% of patients, compared with 24% for conventional imaging, the study said. AuntMinnie.com (free registration)
(1/3)
| Clinical News & Research
| | |
|
- Phase II trials of cardiac imaging agent BFPET underway
FluoroPharma said Phase II trials of its BFPET imaging agent for chronic coronary artery disease have started at Massachusetts General Hospital. In this current study, the fluorine-18-labeled tracer will be compared with Rb-82 and/or other SPECT agents such as sestamibi. Yahoo/Zacks
(1/3)
| Industry Report
| | |
|
- Lantheus extends SPECT agents deal with Japanese firm
Lantheus Medical Imaging has renewed its long-term licensing and distribution deal with Fujifilm RI Pharma covering SPECT imaging agents Cardiolite and Neurolite. As part of the 10-year deal, which took effect Jan. 1, Lantheus will keep providing FRI with the agents in finished form for distribution in Japan. Lantheus will also supply raw materials for developing and marketing in unit dose format. AuntMinnie.com (free registration)
(1/3)
| News from the Field
| | |
|
- Days of plenty are over for biomedical research
As NIH funding for biomedical research has dwindled, scientists are turning to big drugmakers and disease-focused foundations, shifting the focus from basic to translational research, writes Luke Timmerman. The result could be a slew of new drugs, devices and diagnostics over the next decade, he writes. But moving too far away from basic research could bring missed opportunities for "a whole series of bigger breakthroughs that can come only from asking basic, open-ended research questions about how genes, cells, and lower organisms work," he writes. Xconomy
(12/31)
| International Developments
| | |
|
- Polish researchers aim for large-scale production of isotopes
Researchers at POLATOM labs in Swierk, Poland, have developed a new production line for the radioisotopes yttrium-90 and lutetium-177, which were developed by scientists at the Polish National Centre for Nuclear Research for use in treating cancer. Efforts to start pilot production of the isotopes are underway. "The new radioisotope preparations have been named by us Itrapol and Lutapol. They are precursors necessary to produce radiopharmaÂceuticals," said Radioisotope Centre POLATOM Director Proxy for Scientific Matters Renata Mikolajczak. MTB Europe/News release
(1/3)
| Health Policy
| | |
|
- Obama signs "fiscal cliff" bill delaying SGR fee cuts
President Barack Obama on Wednesday signed the American Taxpayer Relief Act of 2012, popularly known as the "fiscal cliff" legislation. The measure delays for one year an almost 27% cut in doctor fees under the Medicare sustainable growth rate formula. The bill, however, compensates for the SGR fix with budget cuts in other areas, including $800 million in fee cuts in radiology and $300 million in cuts in radiation oncology. AuntMinnie.com (free registration)
(1/3)
| Advancing Health Care
| | |
|
| From SNMMI
| | |
|
| SmartQuote
| | |
|
 | Beware the fury of a patient man."
--John Dryden,
British poet, critic and playwright
|
| |
| |
|
Read more at
SmartBrief.com |
|
|
|
| |
| |
| | Recent
SNMMI SmartBrief Issues:
- Thursday, January 03, 2013
- Wednesday, January 02, 2013
- Monday, December 31, 2012
- Friday, December 28, 2012
- Thursday, December 27, 2012
| | | Lead Editor:
Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | |
| |
|
| © 1999-2013 SmartBrief, Inc.®
Legal Information |
|
